Salvage chemotherapy with R-DHAP in patients with relapsed or refractory non-Hodgkin lymphoma
This analysis reports on 72 patients with relapsed or refractory non-Hodgkin lymphoma who were treated with R-DHAP salvage chemotherapy regimen followed by high-dose chemotherapy and stem cell transplantation. The overall remission rate was 58.3%. Median time of follow-up was 28.7 months. Median pro...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
16 Sep 2016
|
| In: |
Cancer investigation
Year: 2016, Volume: 34, Issue: 8, Pages: 361-372 |
| ISSN: | 1532-4192 |
| DOI: | 10.1080/07357907.2016.1212062 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1080/07357907.2016.1212062 Verlag, lizenzpflichtig, Volltext: https://www.tandfonline.com/doi/full/10.1080/07357907.2016.1212062 
|
| Author Notes: | Nadine G.D. Schirmbeck, Ulrich J.M. Mey, Attilio Olivieri, Yon-Dschun Ko, Ulrich Kaiser, Dimitri Flieger, Mathias Witzens-Harig, Ingo G.H. Schmidt-Wolf |
| Summary: | This analysis reports on 72 patients with relapsed or refractory non-Hodgkin lymphoma who were treated with R-DHAP salvage chemotherapy regimen followed by high-dose chemotherapy and stem cell transplantation. The overall remission rate was 58.3%. Median time of follow-up was 28.7 months. Median progression-free survival was 29 months, estimated median overall survival was 37 months. Within a matched pair analysis these results were compared to a group that received DHAP salvage therapy without rituximab showing similar overall response rates and better estimated five-year overall survival of 59.2% versus 43.5%. R-DHAP therapy was shown to be effective and feasible with acceptable toxicity. |
|---|---|
| Item Description: | Gesehen am 14.05.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1532-4192 |
| DOI: | 10.1080/07357907.2016.1212062 |